Table 5.
Univariate and multivariate analysis of prognostic factors for OS
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Treatment (lymph-like/other vs ALL-like/AML-like/NK-T-like) | 2.396 | 1.391-4.125 | .002 | 2.461 | 1.361-4.449 | .003 |
| Age (continuous variable) | 1.026 | 1.011-1.041 | .0007 | |||
| ECOG status 0-2 vs 3-4 | 0.278 | 0.137-0.565 | .001 | 0.268 | 0.124-0.576 | .001 |
| Myelemia, × 109/L | 4.245 | 1.467-12.289 | .008 | 4.696 | 1.365-16.153 | .001 |
| Monocytes, × 109/L | 1.423 | 0.912-2.221 | .1200 | |||
| White blood cells, × 109/L | 0.881 | 0.736-1.0555 | .168 | |||
| Platelets, × 109/L | 0.996 | 0.992-1.000 | .079 | |||
The estimates of the parameters are given with their 95% confidence intervals. A P value < .05 is considered statistically significant.
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio.